Patents
N-phenyl-3-pyrimidine-amine derivatives
Patent Number: 7,329,661This patent covers the treatment of a "proliferative disorder" using a family of compounds which include N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-- ylmethyl-benzamide methanesulfonate. These agents inhibit stem cell factor signalling, as well as signalling of PDGF.
Inventors: Buerger; Hans Michael (Allschwil, CH), Caravatti; Giorgio (Bottmingen, CH), Zimmerman; Juerg (Binningen, CH), Manley; Paul William (Arlesheim, CH), Breitenstein; Werner (Basel, CH), Cudd; Margaret Amelia (Munchenstein, CH)
Assignee: Novartis AG (Basel, CH)
Date of First Priority Issue: Tuesday September 11th, 2001
1 Comment
1 Comment
Buffy coat tube and float system and method
Patent Number: 7,329,534This patent covers a device that is capable of separating various cellular populations, or populations of particulate matter. Essentially, the device addresses the need for an easy to use, effective, and rapid method of collecting the "buffy coat" from a blood population, as well as cells within the buffy coat. The device purifies the cells using axial expansion of blood fluid components layered...
Inventors: Haubert; Thomas D. (Columbus, OH), Wardlaw; Stephen C. (Lyme, CT)
Assignee: Battelle Memorial Institute (Columbus, OH)
Date of First Priority Issue: Thursday October 3rd, 2002
Modulation of cell fates and activities by phthalazinediones
Patent Number: 7,326,690This patent covers a pharmaceutical agent, and numerous derivatives thereof, for manipulation of cellular and stem cell activity. The family of compounds covered are called phthalazinediones, and they have previously been described to possess various anti-inflammatory activities. The patent claims include methods of treatment for metabolic diseases and methods of decreasing metabolic...
Inventors: Henry; Mark O. (North Andover, MA), Lynn; William S. (Hillsborough, NC)
Assignee: Bach Pharma, Inc. (North Andover, MA)
Date of First Priority Issue: Wednesday October 30th, 2002
Decellularized bone marrow extracellular matrix
Patent Number: 7,326,571Numerous patents have been filed on de-cellularized tissues for use as matrices. For example, patent # 6,696,074 teaches that various fetal tissues may be de-cellularized and used as scaffolds. Such scaffolds may be seeded with various differentiated or stem cells, such as
Assignee: Boston Scientific Scimed, Inc. (Maple Grove, MN)
Date of First Priority Issue: Thursday July 17th, 2003
Endoderm cells from human embryonic stem cells
Patent Number: 7,326,572This is one of Geron's numerous patents covering not only composition of matter for various stem cells (licensed from WARF) but also methods of actually differentiating the cells into different other cells that are useful either potentially for therapy or for research use. The current patent covers generation of endoderm through culturing of ES cells with Activin A and/or sodium butyrate.
Inventors: Fisk; Gregory J. (Fremont, CA), Inokuma; Margaret S. (San Jose, CA)
Assignee: Geron Corporation (Menlo Park, CA)
Date of First Priority Issue: Friday December 7th, 2001
Methods and compositions for healing and repair of articular cartilage
Patent Number: 7,323,445This patent covers the regeneration of articular cartilage by administering an osteochondral graft together with purified bone morphogenetic protein (BMP) selected from the group consisting of BMP-2, 4, 5, 6, and 7 and one protein which induces the formation of tendon or ligament tissue selected from the group consisting of BMP-12, BMP-13, and MP52. This patent is very important since 2 members...
Inventors: Zhang; Renwen (Rutherford, NJ), Peluso; Diane (Marshfield, MA), Morris; Elisabeth (Sherborn, MA)
Assignee: Genetics Institute, LLC (Cambridge, MA)
Date of First Priority Issue: Monday February 1st, 1999
Gene transfer into primate embryonic stem cells using VSV-G pseudotyped simian immunodeficiency virus vectors
Patent Number: 7,323,337This patent covers methods of transfecting embryonic stem cells. Specifically, it claims the use of SIV genetically engineered so that the nucleic acid which is being transfected is packaged into an SIV virion. Specific proteins and strains of SIV are covered that are useful for transfection. Numerous techniques for genetic modification of hematopoietic stem cells has previously been patented, for...
Inventors: Hanazono; Yutaka (Tochigi, JP), Ueda; Yasuji (Ibaraki, JP), Kondo; Yasushi (Kyoto, JP), Suzuki; Yutaka (Hyogo, JP)
Assignee: DNAVEC Research Inc. (Ibaraki, JP); Tanabe Seiyaku Co., Ltd. (Osaka, JP)
Date of First Priority Issue: Friday June 8th, 2001
Cell delivery system comprising a fibrous matrix and cells
Patent Number: 7,323,190The current patent covers the delivery of cells using a matrix that is fibrous and the fibers are between 10 nanometers to 1 micrometer in diameter. The fibers are made in such a manner so that they are in contact with the cells. In some of the claims the fibers are comprised of polymers, one type of polymer covered is a linear aliphatic polyester. A specific type of linear aliphatic...
Inventors: Chu; Benjamin (Setauket, NY), Hsiao; Benjamin S. (Setauket, NY), Hadjiargyrou; Michael (Coram, NY), Fang; Dufei (Painted Post, NY), Zong; Xinhua (Centereach, NY), Kim; Kwangsok (Setauket, NY)
Assignee: The Research Foundation at State University of New York (Stony Brook, NY)
Date of First Priority Issue: Friday September 14th, 2001
Production of pancreatic islet cells and delivery of insulin
Patent Number: 7,323,165Numerous approaches have been patented on the treatment of diabetes through regeneration. These range from bone marrow stem cell modification and administration, to generation of islets from embryonic stem cells, to creation of differentiated proliferating
Assignee: The Regents of the University of California (Oakland, CA)
Date of First Priority Issue: Tuesday April 6th, 1999
Unactivated ungulate oocytes to produce a cloned ungulate by nuclear transfer
Patent Number: 7,321,076This patent is of the same family as the original patents on cloning by Dr Wilmut's group. Essentially the patent's overall main claim is represented in the first independent claim which states: Cloning an ungulate comprising: (i) fusing a diploid, ungulate differentiated cell with an unactivated, enucleated metaphase II-arrested oocyte of the same species to reconstruct an embryo; (ii...
Inventors: Campbell; Keith Henry Stockman (Midlothian, GB), Wilmut; Ian (Midlothian, GB)
Assignee: Roslin Institute (Midlothian, GB)
Date of First Priority Issue: Friday August 30th, 1996